We also assessed the ER, PR, and HER2-neu immunohistochemical status of the tumor and observed that among 10 cases with ER-negativity, nine cases (90%) showed stromal CD10 expression, 8 (80%) out of 10 PR negative cases showed stromal CD10 expression. This evidence concerns the gene ESR1 and neoplasm.